Atreca Inc Quick Ratio (BCEL) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Atreca inc   (NASDAQ: BCEL)

Atreca Inc 's Quick Ratio

BCEL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 1.5 a new company low.

Within Major Pharmaceutical Preparations industry 369 other companies have achieved higher Quick Ratio than Atreca Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 988 to 1566.

Explain Quick Ratio?
How much Cash & cash equivalents BCEL´s has?
What are BCEL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BCEL Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change 28.43 % 18.39 % 45.97 % -24.56 % -31.07 %
Y / Y Cash & cash equivalent Change -75.05 % -62.12 % -52.17 % -39.76 % -43.93 %
Quick Ratio MRQ 1.5 3.21 4.01 5.53 7.7
BCEL's Total Ranking # 1566 # 988 # 811 # 649 # 549
Seq. Current Liabilities Change 19.11 % -14.64 % 10.33 % 14.48 % 9.8 %
Seq. Cash & cash equivalent Change -44.5 % -31.66 % -20.01 % -17.77 % -15.73 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 370
Healthcare Sector # 677
Overall Market # 1566


Quick Ratio Statistics
High Average Low
27.95 12.72 1.5
(Sep 30 2020)   (Sep 30 2023)




Financial Statements
Atreca Inc 's Current Liabilities $ 14 Millions Visit BCEL's Balance sheet
Atreca Inc 's Cash & cash equivalent $ 21 Millions Visit BCEL's Balance sheet
Source of BCEL's Sales Visit BCEL's Sales by Geography


Cumulative Atreca Inc 's Quick Ratio

BCEL's Quick Ratio for the trailling 12 Months

BCEL Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 11.11 % -5.44 % -15.62 % -33.96 % -28.25 %
Y / Y Cash & cash equivalent TTM Growth -55.77 % -48.7 % -44.87 % -43.39 % -46.33 %
Quick Ratio TTM 3.52 5.03 6.54 8.61 8.83
Total Ranking TTM # 3699 # 3610 # 3702 # 3302 # 460
Seq. Current Liabilities TTM Growth 6.34 % 3.88 % 10.15 % -8.68 % -9.5 %
Seq. Cash & cash equivalent TTM Growth -25.62 % -20.1 % -16.37 % -11.02 % -13.72 %

Quick ratio ranking by company, industry and sector >> Back to BCEL Financial Strength Comparisons >> Go to Compare BCEL Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q3 2023 to $14.30 millions, cumulative Quick Ratio decreased to 3.52 below the Atreca Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 514 other companies have achieved higher Quick Ratio than Atreca Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 3610 to 3699.

Explain Quick Ratio?
How much Cash & cash equivalents BCEL´s has?
What are BCEL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 515
Healthcare Sector # 1033
Within the Market # 3699


trailing twelve months Quick Ratio Statistics
High Average Low
23.11 12 3.22
(Sep 30 2020)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Mirum Pharmaceuticals Inc   4.10 $ 306.030  Millions$ 74.664  Millions
United Therapeutics Corporation  4.09 $ 2,875.500  Millions$ 703.500  Millions
Nuvectis Pharma inc   4.07 $ 22.059  Millions$ 5.418  Millions
Zymeworks Inc   4.06 $ 295.406  Millions$ 72.847  Millions
Oragenics Inc   4.05 $ 5.767  Millions$ 1.423  Millions
Sarepta Therapeutics Inc   4.05 $ 1,733.542  Millions$ 428.249  Millions
Imunon Inc   4.00 $ 19.377  Millions$ 4.846  Millions
Arcus Biosciences Inc   4.00 $ 799.000  Millions$ 200.000  Millions
Cartesian Therapeutics Inc   3.99 $ 79.603  Millions$ 19.939  Millions
Tg Therapeutics Inc   3.97 $ 229.159  Millions$ 57.678  Millions
Y mabs Therapeutics inc   3.97 $ 86.571  Millions$ 21.812  Millions
Syros Pharmaceuticals Inc   3.95 $ 112.219  Millions$ 28.394  Millions
Puretech Health Plc  3.95 $ 202.827  Millions$ 51.370  Millions
Immunome Inc   3.92 $ 90.641  Millions$ 23.111  Millions
Cyclerion Therapeutics Inc   3.89 $ 9.108  Millions$ 2.341  Millions
Harrow Inc   3.88 $ 73.875  Millions$ 19.029  Millions
Biohaven Ltd   3.87 $ 240.596  Millions$ 62.177  Millions
Zevra Therapeutics Inc   3.84 $ 83.426  Millions$ 21.714  Millions
Inovio Pharmaceuticals Inc   3.83 $ 167.473  Millions$ 43.711  Millions
Aclaris Therapeutics Inc   3.82 $ 103.052  Millions$ 27.010  Millions
Ardelyx inc   3.79 $ 165.080  Millions$ 43.529  Millions
Deciphera Pharmaceuticals Inc   3.79 $ 339.075  Millions$ 89.458  Millions
Uniqure N v   3.78 $ 229.484  Millions$ 60.719  Millions
Kiniksa Pharmaceuticals International Plc  3.76 $ 201.084  Millions$ 53.468  Millions
Xilio Therapeutics Inc   3.76 $ 59.772  Millions$ 15.915  Millions
Talphera Inc   3.75 $ 13.389  Millions$ 3.574  Millions
Aurinia Pharmaceuticals Inc   3.73 $ 344.579  Millions$ 92.292  Millions
Alpine Immune Sciences Inc   3.73 $ 193.453  Millions$ 51.818  Millions
Regulus Therapeutics Inc   3.73 $ 30.782  Millions$ 8.248  Millions
Phio Pharmaceuticals Corp  3.73 $ 8.407  Millions$ 2.256  Millions

Date modified: 2026-09-26T07:38:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.